This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
In today’s rapidly evolving healthcare landscape, pharmaceutical companies are increasingly adopting innovative models to stay competitive. Digitalhealth is at the forefront, aiming to improve patient outcomes and optimize healthcare delivery. A company that has taken a pioneering role in this area is the MEDICE Health Family.
The patient-focused report gets specific about people dealing with asthma, COPD, Type 2 diabetes, heart disease, psoriasis, and atopic dermatitis with a lens on what bio-pharmaceutical manufacturers (biopharma) can do to better support people in managing these conditions.
Biofourmis , a global digitalhealth and clinical trial solutions leader, announces four key partnerships with top pharmaceutical firms. Beyond digital biomarker and endpoint expertise, pharmaceutical partners are leveraging Biofourmis to streamline study timelines through its Digital Clinical Trials solution.
A new report from PwC predicts that new and proposed FDA regulations could open up doors for pharmaceutical companies looking to develop digital tools.
–(BUSINESS WIRE)–Aptar DigitalHealth, a global leader in digitalhealth solutions enhancing the patient experience, today announces the positive results from the SPEED 1 survey, showcasing the impact of the iPUMP connected assistant on adherence to Stallergenes Greers sublingual liquid immunotherapy (SLIT).
In the ever-evolving landscape of pharmaceuticals, innovation has become a guiding force for companies toward a future where healthcare is not only effective but seamlessly integrated into our daily lives. The company envisions a future where connected devices enhance patient care and pharmaceutical packaging simultaneously.
The pharmaceutical landscape is undergoing a momentous transformation, marked by the convergence of cutting-edge technologies that are redefining every aspect of the industry. The first application of AI to the pharmaceutical industry is its use in ramping up and improving new drug discovery.
At the Frontiers Health conference, Eloise McLennan , Deep Dive editor at pharmaphorum, interviewed Fabrizio Connicella , Vice-President Center of Open Innovation & Competence at Chiesi Farmaceutici SpA , to discuss the evolving landscape of pharmaceutical innovation.
In a statement, NEC said it will work with Biomy in enhancing the latter's cloud-based automated digital pathology analytical platform DeepPathFinder to discover new pathological biomarkers. They will later offer the enhanced digital pathology platform to pharmaceutical and biotechnology companies and academic institutions.
Looking for health information online is just part of being a normal, mainstream health consumer, according to the third Rock HealthDigitalHealth Consumer Adoption Survey published this week. adults were online health information hunters. By 2017, 8 in 10 U.S. adults; the poll was fielded in 2017.
When announced, the news was a signal that health care and the larger tech-enabled ecosystem that supports health and well-being is embedded in peoples’ everyday lives. We can expect to see more women-related health tech featured at CES 2022, including on education panels and speaking platforms.
Also: Skin Analytics' Series A contributes to AI-based detection of potential skin cancer; China's LickDoc supports its healthcare big data repository with $102 million.
This news is a signal that health care and the larger tech-enabled ecosystem that supports health and well-being is embedded in peoples’ everyday lives. We can expect to see more women-related health tech featured at CES 2022, including on education panels and speaking platforms.
Trust has become a key currency in provider/patient/supplier relationships: 94% of health executives say treating customers as partners is important to gain trust, according to the DigitalHealth Tech Vision 2018 from Accenture. Accenture’s vision this year is built on five pillars: Citizen AI. Extended Reality. Data Veracity.
Exec Summary: The digitalhealth IPO boom of 2021 saw a surge of companies entering the public market, but the landscape has shifted since then. Why did so many DigitalHealth companies go public in 2021? There were a confluence of factors that fueled the surge of digitalhealth companies going public in 2021: 1.
The Report shows that the world’s leading pharmaceutical companies continue to spurn the opportunity to connect via social media at a local level. Roche Pharmaceuticals 3. Bayer (Pharmaceuticals Division) 4. Pfizer, Janssen, Novartis, Novo Nordisk, AbbVie and Takeda Pharmaceutical have at least 11 local apps available.
But as I write in HealthConsuming: From Health Consumer to Health Citizen , it will take health-baked public policies and stronger privacy rights in America to bolster better personal and community health and fiscal outcomes.
The US is a major market for UK HealthTech exports, think medical devices, diagnostics, and digitalhealth tools. Billion in goods to the US, with pharmaceuticals alone accounting for 8.8 In 2023, the UK exported 60.4 HealthTech, including MedTech and diagnostics, is a chunk of that too, though exact figures vary.
Daewoong Pharmaceutical , a prominent player in the South Korean pharmaceutical industry, has unveiled its groundbreaking drug development system, Daewoong AI System (DAISY). About DAISY DAISY represents the culmination of over 40 years of research and development by Daewoong Pharmaceutical.
Newel Health is well poised to leverage ODD-403’s compelling clinical findings, underscoring its commitment to delivering validated and impactful digitalhealth solutions. About Orion Orion is a globally operating Finnish pharmaceutical company – a builder of well-being.
Stability the safety net and rebuild public health. Address social determinants of health. Accelerate digitalhealth. Secure health data (updating privacy/HIPAA). Note that WHO’s approach to digitalhealth adoption includes equity, access, palliative care, privacy, and security.
Drawing from my background in the pharmaceutical industry, I want to shed light on the challenges of navigating procurement processes within large enterprises. It’s crucial to understand that having just one primary source of revenue, especially from pharmaceutical giants, can pose significant risks.
There’s a gap between the supply of digitalhealth tools that hospitals and health systems offer patients, and what patients-as-consumers need for overall health and wellbeing. Nowhere in the top 10 most commonly provided digital tools is one for price transparency, cost comparing or cost estimating. .
By intelligently combining data from the new Inspire wearable vision testing platform with our robotic diagnostics on the Harmony digitalhealth information platform, we are furthering our Healthcare from the Eye initiative with a truly dynamic digital healthcare ecosystem. For more information, visit www.radiusxr.com.
Simplifying Complexity with AI Drug pricing and access are increasingly difficult to navigate, with healthcare payers and pharmaceutical companies facing inefficiencies, missed opportunities, and delays in delivering therapies to patients. About Lyfegen Lyfegen is a global provider of market access, pricing, and rebate management solutions.
The acquisition of Healint aligns with Aptar DigitalHealth’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digitalhealth deployment. CRYSTAL LAKE, Ill.–(BUSINESS
(Nasdaq: BIIB) to operate and develop digitalhealth solutions for neurological and rare diseases. Nasdaq: BIIB) to operate and develop digitalhealth solutions for neurological and rare diseases. As part of the agreement, Biogen will transfer ownership of select digitalhealth solutions to Aptar DigitalHealth (Aptar).
Bormioli Pharma has a portfolio of pharmaceutical primary packaging made of glass and plastic as well as closure solutions, accessories and dosing systems that is complementary to Gerresheimer. The company manufactures pharmaceutical primary packaging made of glass and plastic as well as closure solutions, accessories and dosing systems.
The PACT Consortium managed by Tufts CSDD and backed by over 30 toptier pharmaceutical organizations and technology providers including Medable seeks to provide the industry with a datadriven blueprint for action. Its not one size fits all. 5 at 9:55am.
Exec Summary: The HealthTech sector is poised for significant M&A activity in 2025, driven by several key trends: DigitalHealth Solutions: The increasing demand for digitalhealth solutions to improve healthcare accessibility and efficiency will drive acquisitions of innovative startups and established players in this space.
Pharmaceuticals are no longer looking for a point-based product, but rather a group of services that engage patients in a way that increases adoption and adherence for medical purposes. One solution is digital therapeutics (DTx). About the author. Enrique Estrada is the Sr. 1 Frost & Sullivan.
23andMe tried to monetize its extensive genetic database by collaborating with pharmaceutical companies for drug research. Although 23andMe claims it anonymizes data, concerns persist about its use, especially with pharmaceutical partnerships like GlaxoSmithKline’s. Handling genetic data responsibly remains a significant privacy issue.
In addition to appointing a new president, TruLite has added two board members: Edmondo Robinson, MD, MBA, is a national leader in digitalhealth and innovation with over 25 years of experience in healthcare delivery, management and leadership.
With so many partners and vendors now participating along the digitalhealth chain, from device manufacturers and researchers to cloud and healthcare providers the digital footprint of patient data is larger than ever. Integration and Regulation As with any form of broad-sweeping digital transformation, integration is key.
This capability is attracting pharmaceutical and life science companies, health care providers and research organizations to take a closer look at Seqster’s offering. Takeda is one of the organizations that has implemented Seqster’s solution, leveraging real-time data for research and patient services.
Aptar DigitalHealth’s SaMD platform offers digitalhealth solutions adapted to the patient’s profile, disease state and treatment plan to empower them during their treatment journey. About Aptar DigitalHealth Aptar Pharma’s DigitalHealth division is part of AptarGroup, Inc.,
Most notably, I call out Ian Morrison who led Institute for the Future (and the health care practice at IFTF) for many years, ten of which I was affiliated with the Institute. I was lucky to collaborate with several of the smartest Yoda-practitioners in scenario planning.
The PACT Consortium managed by Tufts CSDD and backed by over 30 toptier pharmaceutical organizations and technology providers including Medable seeks to provide the industry with a datadriven blueprint for action. Medable will also be presenting with Christina Fawcett, Director of DigitalHealth Delivery at GSK on Wednesday, Feb.
The report found three big shifts in global health citizens’ views on their personal health and health care delivery in the wake of the pandemic: Across all age groups, COVID-19 exacerbated peoples’ concerns about their physical and mental health in a very short time.
Benefiting from the combined capabilities and digital platforms of both organizations, the partnership will provide integrated solutions to pharmaceutical partners aiming to enhance patient experiences. The Iona Mind platform contains low-intensity CBT programs for managing common mental health conditions and general wellbeing.
It’s still the early days, but the FDA’s approval of Proteus DigitalHealth and Otsuka Pharmaceuticals’ Abilify MyCite has changed the discussion of digital technology in healthcare.
The Docquity PAP facilitates the connection among hospitals, HCPs, patients, and pharmaceutical partners on one platform. Enterprise Taxonomy: AI Patient Access Telehealth Clinical decision support Medical devices Analytics Care Quality Care DigitalHealth
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
88 
Let's personalize your content